• PharmAla Biotech signed an agreement with Corealis Pharma for GMP manufacturing of its patented ALA-002 drug product for clinical supply.
• Corealis has begun formulation research and development; manufacturing of the first GMP batch will follow completion of development activities.
• ALA-002 will initially be developed as a 50 mg capsule.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmala Biotech Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050800PRIMZONEFULLFEED9870865) on November 05, 2026, and is solely responsible for the information contained therein.